Clinical validation of circulating GDF15/MIC‐1 as a marker of response to docetaxel and survival in men with metastatic castration‐resistant prostate cancer

Ähnliche Einträge

• PIK3/Akt/mTOR pathway alterations in metastatic castration‐sensitive prostate cancer
  von: Philip Sutera, et al.
  Veröffentlicht: (2024)
• Bellmunt risk score as a survival predictor in patients with metastatic castration‐resistant prostate cancer
  von: Thomas Büttner, et al.
  Veröffentlicht: (2024)
• Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration‐resistant prostate cancer patients
  von: Tokiyoshi Tanegashima, et al.
  Veröffentlicht: (2024)
• Real‐world prevalence of adverse events with first‐line systemic therapies among patients with metastatic castration‐sensitive prostate cancer
  von: Umang Swami, et al.
  Veröffentlicht: (2024)
• A panel‐based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration‐resistant prostate cancer
  von: Daniel Boiarsky, et al.
  Veröffentlicht: (2024)